TG4010, a therapeutic cancer vaccine, expressing MUC1 as well as interleukin 2, and is combine with PD-L1 immune inhibitor nivolumab, has been approved by the FDA for the first-line treatment of patients with NSCLC [51]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.